Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT04302220
Active, not recruiting Observational

Myopic Optic Neuropathy in Chinese High Myopia Population

NCT04302220 · tracked via the Priya Life Science China tracker
Sponsor
Sun Yat-sen University
Phase
Observational
Started
2019-06-06
Last updated
2024-12-09

Condition(s) studied

Eye Diseases

Study summary

This study intends to establish a registry cohort to enroll patients with high myopia to study the natural course of myopic optic neuropathy in Chinese adult population.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria * Age ≥18 years * Equivalent spherical ≤-6D or axial length ≥26.5mm * Best corrected visual acuity ≥ 6/12 Exclusion Criteria * Unwilling or unable to give consent, or unable to return for scheduled protocol visits. * Glaucoma secondary to penetrating keratoplasty, trauma, steroids, retinal disease/surgery, or neovascular disease. * Obvious corneal and iris lesions, or severe cataracts interfering with fundus examinations, VF test or monophthalmia. * Need for ocular surgery/laser or anticipated need for cataract surgery during the study period. * Other serious systemic diseasesf (i.e. hypertension, heart disease, diabetes, or rheumatic immune system diseases); * Pregnant or nursing women

Primary outcome measure(s)

  • Progression of glaucoma within 36 months — 3 years
    Structural and functional changes of glaucoma using visual field, stereoscopic fundus photography.

Trial sites (1)

FacilityCityRegionStatus
Zhongshan Ophthalmic Center Guangzhou Guangdong

More Sun Yat-sen University trials in China

Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. Active, not recruiting
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL Recruiting
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC Starting soon
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Enrolling by invitation
Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma Recruiting

Other trials for the same condition

Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis Active, not recruiting
The Proactive Ophthalmic Examination Cohort Recruiting
Shanghai Children and Adolescent Diabetes Eye Study Recruiting
Repeated Low-Level Red-Light Therapy for Shortening Axial Length Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04302220 on ClinicalTrials.gov ↗ ← All trials in China